Counterfeit Drugs – The Challenges of a Deadly Global Epidemic
For years, the average person who heard the phrase “knock offs” would immediately think of counterfeit versions of brand name luxury goods. While counterfeiters continue to target those types of goods, they are by no means the most nefarious or sophisticated category of counterfeiters. Counterfeiters have effectively targeted almost every type of consumer product imaginable, including the drugs and medical diagnostic devices that consumers rely on for their health and safety.
Consumers and pharmaceutical companies are not the only ones facing this growing concern. Pharmacies, hospitals, doctors, insurance companies, and others who are involved in marketing, distributing, or purchasing pharmaceutical and medical device products are at risk.
On June 18, 2013, the Gibbons Institute of Law, Science & Technology at Seton Hall Law School will present a CLE program featuring industry leaders who will provide an overview of the counterfeit drug problem and discuss strategies to combat counterfeiters in the United States and worldwide.
The panelists include:
- Catherine A. Begley, Regional Security Director for the North America Region, Merck
- Kathleen H. Dooley, Partner, McGuireWoods LLP
- Owen J. McKeon, Director, Intellectual Property Department, Gibbons P.C.
- David W. Opderbeck, Professor of Law and Director, Gibbons Institute of Law, Science & Technology
- Estelle J. Tsevdos, Ph.D., Director, Intellectual Property Department, Gibbons P.C.
To learn more about the issues surrounding the counterfeit drug problem, you can read Counterfeit Drugs – The Challenges Of A Deadly Global Epidemic by Owen McKeon, which was published in the June edition of the Association of Corporate Counsel New Jersey Chapter Newsletter.